Scancell

Scancell's mission is to create a cancer-free future by developing safe, effective, and accessible active immunotherapies. Its core achievement is the advancement of two distinct technology platforms—Immunobody® for DNA vaccines and Moditope® for citrullinated peptide vaccines—into clinical trials, with a lead Phase 3 program in melanoma. The company's strategy focuses on combining its off-the-shelf therapies with standard checkpoint inhibitors to improve outcomes in hard-to-treat cancers, while also exploring earlier-stage antibody assets through its Glymab subsidiary.

Scancell's core platforms are Immunobody® for DNA-based vaccines that target antigens to dendritic cells via an Fc domain, and Moditope® for peptide vaccines targeting citrullinated neoantigens presented via the MHC-II pathway.

Scancell competes with personalized neoantigen vaccine developers (e.g., BioNTech, Moderna) and other off-the-shelf vaccine companies. Its differentiation stems from its two novel platforms, off-the-shelf format, and mechanistic focus on enhancing T-cell responses to synergize with checkpoint inhibitors.